Divi's Laboratories Limited Earnings Summary — Q4 FY2026
Divi's Labs Reports Record Quarterly Revenue and Strong Net Profit Growth in Q4 FY2026
Key Takeaways
- Revenue hit a quarterly record of ₹2,831 Cr, reflecting strong demand in core API and custom synthesis segments.
- Net Profit surged nearly 29% sequentially to ₹751 Cr, supported by higher other income and effective tax management.
- Capital Work-in-Progress (CWIP) skyrocketed to ₹2,113 Cr, signaling a massive upcoming capacity expansion phase.
- The balance sheet remains exceptionally strong with negligible debt and total reserves exceeding ₹16,700 Cr.
- Operating margins (OPM) stabilized at 33%, showcasing the company's resilient cost leadership despite global pricing pressures.
- Annual revenue surpassed the ₹10,000 Cr milestone for the first time in the company's history.
Management Guidance
Management focus remains on long-term capacity building through internal accruals and maintaining high compliance standards with global regulators.
Sentiment Shift
Improving
A strong sequential recovery in net profit and record-breaking topline performance indicates the company is entering a new growth leg.
Outlook
The outlook is highly positive driven by the commissioning of massive new capacities currently in CWIP and a sustained dominant position in high-volume generic APIs.
From the Annual Report (Key Quotes)
“The company maintains a near-debt-free status while funding massive capital expenditures from internal accruals.”
“Divi's is characterized by industry-leading margins and a robust balance sheet.”
“Leadership has successfully navigated USFDA inspections with minimal disruptions compared to peers.”
Earnings Call Transcript — Q4 FY2026
Transcript is fetched on demand to save crawl credits. Click below to load the latest earnings call transcript for this quarter.
This summary is AI-generated from Divi's Laboratories Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.